CCAM BIOTHERAPEUTICS
cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune system to attack tumors. CM-10 binds CEACAM1, a protein used by cancer cells to suppress the immune system. CM-10 abrogates this effect, leading to a cancer specific immune response in patients.
CCAM BIOTHERAPEUTICS
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2009-01-01
Address:
Qiryat Shmona, HaZafon, Israel
Country:
Israel
Website Url:
http://www.ccam-bio.com
Total Employee:
11+
Status:
Closed
Contact:
972 4 681 8829
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Nginx DigiCert SSL CloudFront Google Adsense AdBlock Acceptable Ads Google Adsense For Domains Thawte SSL
Similar Organizations
Juno Therapeutics
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Current Employees Featured
Founder
Investors List
Arkin Holdings
Arkin Holdings investment in Series A - cCAM Biotherapeutics
OrbiMed
OrbiMed investment in Series A - cCAM Biotherapeutics
Pontifax
Pontifax investment in Series A - cCAM Biotherapeutics
Official Site Inspections
http://www.ccam-bio.com
- Host name: 104.247.82.54
- IP address: 104.247.82.54
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "cCAM Biotherapeutics"
cCAM Biotherapeutics - Crunchbase Company Profile & Funding
Sep 15, 2012 cCAM Biotherapeutics is a pre-clinical stage company developing immunotherapies for cancer. cCAM's lead agent, CM-10, is an immunomodulatory antibody …See details»
Merck Enhances Immuno-Oncology Portfolio with Acquisition of …
Jul 28, 2015 About cCAM Biotherapeutics. Founded in 2010 and led by Tehila Ben-Moshe, Ph.D., cCAM is a biopharmaceutical company focused on the discovery and development of …See details»
cCAM Biotherapeutics Company Profile 2024: Valuation, Investors ...
CCAM Biotherapeutics General Information Description. Developer of novel immunotherapies for different cancer indications. The company's lead agent is CM-10, an immunomodulatory …See details»
cCam Biotherapeutics - Products, Competitors, Financials, …
Investors of cCam Biotherapeutics include Merck & Co, Pontifax, Arkin Holdings, OrbiMed Advisors, Roche and 3 more. Loading... 498 Seventh Avenue 12th floor New York, NY 10018See details»
cCAM Biotherapeutics - Overview, News & Similar companies
View cCAM Biotherapeutics (www.ccam-bio.com) location in Northern District, Israel , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»
cCAM Biotherapeutics - VentureRadar
CCAM Biotherapeutics develops novel immunotherapies for different cancer indications. cCAM's lead agent, CM-10, is an immunomodulatory antibody that harnesses the patient's immune …See details»
cCAM Biotherapeutics - Monoclonal Antibodies for Cancer …
CCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer. The company's lead product, CM-24, is a phase 1 …See details»
Merck Enhances Immuno-Oncology Portfolio acuiring cCAM
Jul 29, 2015 About cCAM Biotherapeutics Founded in 2010 and led by Tehila Ben-Moshe, Ph.D., cCAM is a biopharmaceutical company focused on the discovery and development of …See details»
cCAM Biotherapeutics Announces Initiation of Phase 1 Trial of CM …
Apr 23, 2015 Dr. Tehila Ben-Moshe, Chief Operation Officer, cCAM Biotherapeutics, stated, "We are pleased to have our CM-24 Phase 1 clinical trial underway.See details»
Capital BioVentures Announces Inaugural Cohort for Ottawa …
14 hours ago The organization is actively looking to expand its lab-space footprint to accommodate additional demand for placements. About Capital BioVentures.See details»
Funding from Ontario government launches OmniaBio Inc.
Development and manufacturing organization (CDMO) for cell and gene therapies (CGTs) – the largest facility of its kind in Canada. “We are grateful to the Government of Ontario, through …See details»
OmniaBio Inc. - CCRM
Organization (CDMO) for the manufacture of cell and gene therapies. OmniaBio will provide pivotal/Phase III and commercial-scale manufacturing of gene-modified cells and viral vectors …See details»
Meet Mitch: The CEO leading Canada’s largest CDMO dedicated to ...
Sep 15, 2022 The new contract development and manufacturing organization (CDMO) will focus on producing gene-modified cell therapies and viral vectors compliant with Good …See details»
Merck Enhances Immuno-Oncology Portfolio with Acquisition of …
Jul 28, 2015 "Merck's excellence and leadership in immuno-oncology provides a strong foundation for advancing CM-24, for the treatment of people with cancer," said Pini Orbach, …See details»
OmniaBio, CCRM and Stakeholders Celebrate Commencement of …
October 6, 2022 (Hamilton, ON) – OmniaBio Inc., a commercial-stage contract development and manufacturing organization (CDMO) focused on cell and gene therapies (CGTs), has broken …See details»
OmniaBio: Bringing Maturity to Cell and Gene Therapy (Drone Video)
MaRS Centre, West Tower 661 University Avenue, Suite 1002 Toronto, Ontario M5G 1M1 Canada t: 416-978-3751 f: 416-978-1368See details»
OmniaBio’s Impact and Future with Mitchel Sivilotti
Apr 27, 2024 Mitch Sivilotti, CEO of OmniaBio Inc., shared with CanadianSME Small Business Magazine how OmniaBio is propelling Canada to the forefront of cell and gene therapy (CGT) …See details»
OMNIABIO: POSITIONING ONTARIO TO LEAD IN A GLOBAL
May 4, 2023 In September 2022, the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing announced it had made a $10.5 million …See details»
CCAM - European Partnership on Connected, Cooperative and …
Exploit the full systemic benefits of new mobility solutions enabled by CCAM: increased safety, reduced environmental impacts, and inclusiveness. Discover the Association CCAM …See details»
Congenital pulmonary airway malformation - Radiopaedia.org
Aug 22, 2024 CPAMs were previously termed congenital cystic adenomatoid malformations (CCAM). Epidemiology. They account for ~25% of congenital lung lesions. The estimated …See details»